Cellectar Biosciences, Inc. CLRB
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -59.15%
- 1 year
- -63.04%
- Open
- 1.20
- Prev close
- 1.22
- Mkt cap
- 11.39M
- Vol
- 55.29K
- Avg vol
- 87.96K
- EPS
- -3.46
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.18
- High
- 1.21
- Forward P/E
- -0.10
- Beta
- 1.01
- Short ratio
- 8.34
- Inst. own
- 34.55%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.60
- 200-d avg
- 2.48
- 1y target
- 5.67
News
-
5 days ago benzinga.com
Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential…
5 days ago globenewswire.com
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential…
2 weeks ago globenewswire.com
Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenström Macroglobulinemia
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16…
3 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) stock moved upwards by 34.0% to $6.34 during Tuesday's pre-market session. The company's market cap stands at $2.4 million. Option Care Health (NASDAQ:OPCH) stock…
1 month ago globenewswire.com
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately…
1 month ago benzinga.com
Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying
Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to…
2 months ago seekingalpha.com
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
2 months ago seekingalpha.com
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
2 months ago benzinga.com
Cellectar Biosciences Q2 2026 Earnings Call Transcript
On Thursday, Cellectar Biosciences (NASDAQ:CLRB) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by…
2 months ago globenewswire.com
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program
-
2 months ago benzinga.com
Cellectar Biosciences Q2 EPS $(0.57) Misses $(0.48) Estimate
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.48) by 18.75 percent. This is a 83.19 percent increase over…
2 months ago defenseworld.net
Analysts Set Cellectar Biosciences, Inc. (NASDAQ:CLRB) PT at $11.00
Cellectar Biosciences, Inc. (NASDAQ: CLRB - Get Free Report) has been given an average rating of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports.…
3 months ago globenewswire.com
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for…
-
3 months ago benzinga.com
Cellectar Biosciences Announces Publication Of Results From Phase 1 Dose-Escalation Study Evaluating Iopofosine I 131 In Combination With Low-Dose Dexamethasone In 31 Patients With Heavily Pretreated R/R MM
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple MyelomaPublication Supports Continued Development of Iopofosine I 131 as a Novel…
3 months ago globenewswire.com
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
Cellectar Biosciences To Highlight Efficacy Results From Phase 2 CLOVER WaM Clinical Trial Of Iopofosine I 131 To Treat r/r WM At 2026 ASCO
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi TherapyPlans to Initiate Phase 3…
5 months ago globenewswire.com
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3…
-
5 months ago benzinga.com
Cellectar Biosciences Files Prospectus For Offering Of Up To 51.2M Shares Of Common Stock By Selling Stockholders
https://www.sec.gov/Archives/edgar/data/1279704/000110465926063918/tm2614975d1_s1.htm
-
5 months ago benzinga.com
Ladenburg Thalmann Assumes Cellectar Biosciences at Buy, Announces Price Target of $10
Ladenburg Thalmann analyst Kevin DeGeeter assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and announces Price Target of $10.
5 months ago seekingalpha.com
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
5 months ago globenewswire.com
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of…
5 months ago globenewswire.com
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for…
5 months ago zacks.com
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
5 months ago benzinga.com
What's Going With Cellectar Biosciences Stock On Wednesday?
Cellectar Biosciences Inc (NASDAQ:CLRB) shares are down during Wednesday's premarket session after the stock closed almost 12% higher on Tuesday after positive clinical trial data and financing…
6 months ago benzinga.com
Crude Oil Down 4%; PayPal Shares Fall After Q1 Results
US stocks rise, Nasdaq gains 1%. Dow up 0.57%, Nasdaq up 1.03%, S&P 500 up 0.84%. Materials up 2.1%, financials down 0.2%. PayPal shares fall 9%.
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
6 months ago benzinga.com
Dow Jumps Over 300 Points; Pfizer Posts Upbeat Earnings
US stocks rise, Dow gains 300 points. Materials jump 1.8%, real estate falls 0.2%. Pfizer's Q1 earnings beat expectations. Asian markets close lower.
6 months ago benzinga.com
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses
Cellectar Biosciences, Inc. (NASDAQ:CLRB) shares are up during Tuesday's trading session as the company announced promising results from its Phase 2b CLOVER WaM clinical trial.
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
6 months ago benzinga.com
Market-Moving news for May 5th
PINS: 19% | Pinterest shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates. CLRB: 145% | Cellectar Biosciences…
6 months ago globenewswire.com
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory…
6 months ago globenewswire.com
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Oversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital…
-
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
9 months ago benzinga.com
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
-
11 months ago benzinga.com
Earnings Scheduled For November 13, 2025
Earnings Scheduled For November 13, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
Earnings Scheduled For August 14, 2025
Earnings Scheduled For August 14, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
1 year ago benzinga.com
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
1 year ago benzinga.com
US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings
US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings
-
1 year ago benzinga.com
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket